Figure 1.

Duration of OHR (A) and MCyR (B). Duration of response was calculated from the first date of response to confirmed loss, treatment discontinuation due to progressive disease or death, or death within 30 days of the last dose of study drug; responders without events were censored at the last follow‐up visit. 2L, Second‐line (prior imatinib only); ≥3L, third‐/fourth‐line (imatinib followed by dasatinib and/or nilotinib); ALL, acute lymphoblastic leukemia; AP, accelerated phase; BP, blast phase; CI, confidence interval; CML, chronic myeloid leukemia; MCyR, major cytogenetic response; NR, not reached; NE, not evaluable; OHR, overall hematologic response.